Dana-Farber Cancer Institute at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Dana-Farber Cancer Institute takes part in 24 sessions at ESMO 2026 in Madrid. Its program centres on breast cancer, from antibody-drug conjugates in HER2-positive disease to endocrine therapy choices in hormone receptor-positive disease. Other sessions cover kidney cancer immunotherapy trials, personalised cancer vaccines, drug selection in prostate cancer and biomarkers for non-small cell lung cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Dana-Farber Cancer Institute Boston, MA | |
Cancer treatment and research institute in Boston, Massachusetts, and a teaching affiliate of Harvard Medical School. | Satellite Fri Oct 23 10:15–10:40 Talk Fri Oct 23 14:10–14:30 Personalising vaccines using peptides, DNA, mRNA and more Melanoma & skin cancers Chair Fri Oct 23 16:15–17:00 The best is yet to come: Immune modulating approaches in neuro- oncology Sarcoma, CNS, head & neck and rare cancers Satellite Fri Oct 23 18:20–18:30 Resectable NSCLC: Personalized treatment selection and patient support to optimize outcomes Lung & thoracic cancersBiomarkers & precision oncology Satellite Fri Oct 23 19:15–19:30 From breakthrough to backbone: The evolving role of immunotherapy across stages of Lung & thoracic cancersBiomarkers & precision oncology Chair Sat Oct 24 08:30–10:00 Rapid oral 1: NSCLC, metastatic Lung & thoracic cancers Abstract Sat Oct 24 08:50–09:00 Abstract Sat Oct 24 09:10–09:22 Invited Discussant LBA74 and 2636RO Lung & thoracic cancers Abstract Sat Oct 24 10:20–10:25 Satellite Sat Oct 24 13:20–13:40 Recent Updates in Resectable LA HNSCC Sarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 13:40–14:10 MDT Case Discussion Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 17:18–17:30 LBA3 - Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers Satellite Sat Oct 24 18:40–18:55 Satellite Sat Oct 24 18:55–19:05 Interactive panel discussion Breast cancer Satellite Sat Oct 24 19:20–19:30 Interactive panel discussion Breast cancer Satellite Sat Oct 24 19:40–19:50 Interactive panel discussion Breast cancer Abstract Sun Oct 25 08:30–08:40 Talk Sun Oct 25 08:45–09:00 Chair Sun Oct 25 10:15–11:45 Talk Sun Oct 25 10:15–10:35 Abstract Sun Oct 25 10:35–10:45 Invited Discussant 690O and 691O Sarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 11:15–11:30 Satellite Sun Oct 25 13:35–13:55 Deep Dive: The Pivotal Evidence Base in nmCRPC Genitourinary cancers Satellite Sun Oct 25 13:45–14:05 Satellite Sun Oct 25 13:55–14:25 Abstract Sun Oct 25 14:45–14:50 Abstract Sun Oct 25 15:39–15:44 Satellite Sun Oct 25 18:38–19:33 Satellite Sun Oct 25 18:40–19:10 ADC Biomarkers and their Current Role in Patients with NSCLC with Actionable Genomic Lung & thoracic cancersBiomarkers & precision oncology Satellite Sun Oct 25 19:33–19:48 Satellite Sun Oct 25 19:48–19:58 Ask the Expert: Panel Discussion and Audience Q&A Breast cancer Talk Mon Oct 26 10:15–10:35 Presentation by Expert Genitourinary cancers Chair Mon Oct 26 10:30–11:15 Abstract Mon Oct 26 10:50–10:55 Abstract Mon Oct 26 17:30–17:42 Invited Discussant LBA11 Gynaecological cancersSarcoma, CNS, head & neck and rare cancers |
Instantly find 20 buyers from Dana-Farber Cancer Institute
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction